Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1611747 · FYE Dec 31 · Prices AT CLOSE 2026-08-28 (USD) Last $2.51 · Day −6.34% · Mkt cap $3.7B · 1Y −82.8% · Off 52W high −85.1% · Vol (1Y) 117.4% Price2023-09-07 → 2026-08-28 SCNI close: $133 on 2023-09-07 to $3 on 2026-08-28. Split-adj closes · 240 of 742 · price returnⓘ At a glance | Short interest0.0% of sh out | | Days to cover1.0d | | 13F net flow (QoQ)−0.00% | | Top-10 13F concentration100.0% |
SI 2026-08-14 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Sales (TTM)$1.3M | | Earnings (TTM)-$8.3M | | ROE−91.9% | | Net margin−633.6% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD−64.7% | | 1Y−82.8% | | Since incept. (ann.)−73.7% |
Total return · from 2023-09-07ⓘ Risk | Ann. volatility (1Y)117.4% | | Ann. volatility (3Y)111.3% | | Sharpe (1Y)−0.99 | | Sharpe (3Y)−0.69 | | Max drawdown (1Y)−86.0% | | Max drawdown (3Y)−98.3% | | Beta (3Y vs SPY)1.67 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| XTX Topco Ltd | 24,041 | $13,283 | 0.00% | −11.9% | | RHUMBLINE ADVISERS | 1,878 | $1,037 | 0.00% | +0.0% | | UBS Group AG | 919 | $524 | 0.00% | −47.4% | | MORGAN STANLEY | 58 | $33 | 0.00% | +0.0% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2023-05-15 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2023-03-31 | 2023-05-15 | — | — | — | — | | 2022-03-31 | — | — | — | — | — |
As-reported XBRLⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
|
